Cenerimod 0.5 mg
( DrugBank: Cenerimod / KEGG DRUG: Cenerimod )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
49 | 全身性エリテマトーデス | 9 |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
Showing 1 to 9 of 9 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-001808-11-GR (EUCTR) | 29/07/202020200729 | 16/07/202020200716 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) - CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ... | Idorsia Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 325 | Phase 2 | United States;Czechia;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Poland;Romania;Bulgaria;Georgia;Germany;China United States;Czechia;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian F ... | ||
2 | EUCTR2018-001808-11-DE (EUCTR) | 04/10/201920191004 | 18/10/201820181018 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) - CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Phase 2 | United States;Taiwan;Thailand;Spain;Ukraine;Turkey;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Poland;Romania;Bulgaria;Georgia;Germany;China United States;Taiwan;Thailand;Spain;Ukraine;Turkey;Israel;Russian Federation;United Kingdom;Italy;Fr ... | ||
3 | EUCTR2018-001808-11-PL (EUCTR) | 17/05/201920190517 | 15/05/201920190515 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) - CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod ... | Idorsia Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 325 | Phase 2 | Georgia;Germany;Romania;Bulgaria;United States;Philippines;Czechia;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Poland Georgia;Germany;Romania;Bulgaria;United States;Philippines;Czechia;Taiwan;Greece;Spain;Thailand;Ukra ... | ||
4 | EUCTR2018-001808-11-BG (EUCTR) | 20/03/201920190320 | 06/12/201820181206 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) - CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod ... | Idorsia Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 325 | Phase 2 | United States;Philippines;Czechia;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Mexico;Poland;Romania;Bulgaria;Georgia;Germany United States;Philippines;Czechia;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian F ... | ||
5 | EUCTR2018-001808-11-HU (EUCTR) | 08/02/201920190208 | 22/11/201820181122 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 20.0;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod ... | Idorsia Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Taiwan;Thailand;Spain;Ukraine;Turkey;Lithuania;Russian Federation;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Poland;Romania;Bulgaria;Georgia;Germany;China United States;Taiwan;Thailand;Spain;Ukraine;Turkey;Lithuania;Russian Federation;Israel;United Kingdo ... | ||
6 | EUCTR2018-001808-11-ES (EUCTR) | 24/01/201920190124 | 16/11/201820181116 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 20.0;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Phase 2 | United States;Hong Kong;Taiwan;Spain;Thailand;Ukraine;Lithuania;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Mexico;Poland;Romania;Bulgaria;Georgia;Germany;China United States;Hong Kong;Taiwan;Spain;Thailand;Ukraine;Lithuania;Turkey;Russian Federation;Israel;Ita ... | ||
7 | EUCTR2018-001808-11-FR (EUCTR) | 14/01/201920190114 | 31/08/201820180831 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 20.0;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Product Name: Cenerimod ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Phase 2 | United States;Taiwan;Thailand;Spain;Ukraine;Turkey;Lithuania;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Mexico;Poland;Romania;Bulgaria;Georgia;Germany;China United States;Taiwan;Thailand;Spain;Ukraine;Turkey;Lithuania;Russian Federation;Israel;United Kingdo ... | ||
8 | NCT03742037 (ClinicalTrials.gov) | December 21, 201820181221 | 12/11/201820181112 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Efficacy and Safety of Four Doses of CenerimodCompared to Placebo in Adult Subjects With Active Syst ... | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE) A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evalu ... | Systemic Lupus Erythematosus | Drug: Cenerimod 0.5 mg;Drug: Cenerimod 1 mg;Drug: Cenerimod 2 mg;Drug: Cenerimod 4 mg;Drug: Placebo | Idorsia Pharmaceuticals Ltd. | NULL | Completed | 18 Years | 75 Years | All | 427 | Phase 2 | United States;Bulgaria;Chile;Czechia;France;Georgia;Greece;Hungary;Israel;Italy;Mexico;Philippines;Poland;Romania;Russian Federation;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;Germany;Lithuania United States;Bulgaria;Chile;Czechia;France;Georgia;Greece;Hungary;Israel;Italy;Mexico;Philippines;P ... |
9 | EUCTR2018-001808-11-GB (EUCTR) | 17/12/201820181217 | 17/09/201820180917 | A research study to evaluate the effects of a new oral drug called cenerimod in adults with Systemic Lupus Erythematosus disease A research study to evaluate the effects of a new oral drug called cenerimodin adults with Systemic ... | A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) - CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalu ... | Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Moderate to severe systemic lupus erythematosus MedDRA version: 21.1;Level: PT;Classification code 1 ... | Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ACT-334441 Product Name: Cenerimod Product Code: ACT-334441 INN or Proposed INN: Cenerimod Other descriptive name: ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 325 | Phase 2 | United States;Czechia;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Mexico;Poland;Romania;Georgia;Bulgaria;Germany United States;Czechia;Philippines;Taiwan;Greece;Spain;Thailand;Ukraine;Turkey;Chile;Israel;Russian F ... |